The Use of Soluble Fibrin in Evaluating the Acute and Chronic Hypercoagulable State

• References

• 1 Janmey PA, Erdile L, Bale MD, Ferry JD. Kinetics of fibrin oligomer formation observed by electron microscopy. Biochemistry 1983; 22: 4336-4340.
• 2 Wiltzius P, Dietler G, Kanzig W, Hofmann V, Haberli A, Straub PW. Fibrin aggregation before sol–gel transition. Biophys J 1982; 38: 123-132.
• 3 Olexa SA, Budzynski AZ. Evidence for four different polymerization sites involved in human fibrin formation. Proc Natl Acad Sci USA 1980; 77: 1374-1378.
• 4 Olexa SA, Budzynski AZ. Localization of a fibrin polymerization site. J Biol Chem 1981; 256: 3544-3549.
• 5 Mosesson MW. Fibrinogen and fibrin polymerization: appraisal of the binding events that accompany fibrin generation and fibrin clot assembly. Blood Coagul Fibrinolysis 1997; 8: 257-267.
• 6 Brass EP, Forman WB, Edwards RV, Lindan O. Fibrin formation: the role of the fibrinogen–fibrin monomer complex. Thromb Haemost 1976; 31: 36-48.
• 7 Usero JL, Burguillo FJ, Izquierdo C, Del Arco A, Herraez MA. The fibrinogen–fibrin complex: stoichiometry and negative cooperativity. Thromb Res 1985; 39: 379-386.
• 8 Williams JE, Hantgan RR, Hermans J, McDonagh J. Characterization of the inhibition of fibrin assembly by fibrinogen fragment D. Biochem J 1981; 197: 661-668.
• 9 Belitser VA, Varetskaja TV, Malneva GV. Fibrinogen–fibrin interaction. Biochim Biophys Acta 1968; 154: 367-375.
• 10 Latallo ZS, Fletcher AP, Alkjaersig N, Sherry S. Inhibition of fibrin polymerization by fibrinogen proteolysis products. Am J Physiol 1962; 202: 681-686.
• 11 Belitser VA, Pozdnjakova TM, Platonova TN, Vovk EV. Fibrin–fragment D complex formation. Thromb Res 1981; 21: 565-572.
• 12 Knoll D, Hantgan R, Williams J, McDonagh J, Hermans J. Characterization of soluble polymerized fibrin formed in the presence of excess fibrinogen fragment D. Biochemistry 1984; 23: 3708-3715.
• 13 Janus TJ, Lewis SD, Lorand L, Shafer JA. Promotion of thrombin-catalyzed activation of factor XIII by fibrinogen. Biochemistry 1983; 22: 6269-6272.
• 14 Lewis SD, Janus TJ, Lorand L, Shafer JA. Regulation of formation of factor XIIIa by its fibrin substrates. Biochemistry 1985; 24: 6772-6777.
• 15 Greenberg CS, Achyuthan KE, Fenton JW. Factor XIIIa formation promoted by complexing of α-thrombin, fibrin, and plasma factor XIII. Blood 1987; 69: 867-871.
• 16 Greenberg CS, Achyuthan KE, Rajagopalan S, Pizzo SV. Characterization of the fibrin polymer structure that accelerates thrombin cleavage of plasma factor XIII. Arch Biochem Biophys 1988; 262: 142-148.
• 17 Gron B, Filion Myklebust C, Bennick A, Nieuwenhuizen W, Matsueda GR, Brosstad F. Early cross-linked fibrin in human plasma contains α-polymers with intact fibrinopeptide A. Blood Coagul Fibrinolysis 1992; 3: 731-736.
• 18 Pfitzner SA, Dempfle CE, Heene DL. Fibrin detected in plasma of patients with disseminated intravascular coagulation by fibrinspecific antibodies consists primarily of high molecular weight factor XIIIa-crosslinked and plasmin-modified complexes partially containing fibrinopeptide A. Thromb Haemost 1997; 78: 1069-1078.
• 19 Wiman B, Ranby M. Determination of soluble fibrin in plasma by a rapid and quantitative spectrophotometric assay. Thromb Haemost 1986; 55: 189-193.
• 20 Collen D, Lijnen HR. The fibrinolytic system in man. Crit Rev Oncol Hematol 1986; 4: 249-301.
• 21 Gron B, Bennick A, Nieuwenhuizen W, Brosstad F. Normal and fibrinaemic patient plasma contain high-molecular weight crosslinked fibrin(ogen) derivatives with intact fibrinopeptide A. Thromb Res 1990; 57: 259-270.
• 22 Shainoff JR, Smejkal GB, DiBello PM, Mitkevich OV, Levy PJ, Dempfle CE, Lill H. Isolation and characterization of the fibrin intermediate arising from cleavage of one fibrinopeptide A from fibrinogen. J Biol Chem 1996; 271: 24129-24137.
• 23 Shainoff JR, Dardik BN. Effects of cross-linking on clearance of circulating α-fibrin monomer and its complexes. J Lab Clin Med 1990; 115: 314-323.
• 24 Graeff H, Hafter R, Bachmann L. Subunit and macromolecular structure of circulating fibrin from obstetrics patients with intravascular coagulation. Thromb Res 1979; 16: 313-328.
• 25 Francis CW, Marder BJ, Martin SE. Plasmic degradation of crosslinked fibrin, I. Structural analysis of the particulate clot and indentification of new macromolecular soluble complexes. Blood 1980; 56: 456-464.
• 26 Gaffney PJ, Joe F, Mahmoud M. Giant fibrin fragments derived from crosslinked fibrin, structure and clinical implication. Thromb Res 1980; 20: 647-662.
• 27 Veklich Y, Francis CW, White J, Weisel JW. Structural studies of fibrinolysis by electron microscopy. Blood 1998; 92: 4721-4729.
• 28 Lasch HG, Kreke HJ, Rodriguez-Erdmann F, Sessner HH, Schütterle G. Verbrauchskoagulopathien: pathogenese und therapie. Folia Haematol Leipz 1961; 6: 325-331.
• 29 Lasch HG, Heene DL, Huth K, Sandritter W. Pathophysiology, clinical manifestations and therapy of consumption-coagulopathy (‘Verbrauchskoagulopathie’). Am J Cardiol 1967; 20: 381-391.
• 30 Soria J, Soria C, Ryckewaert JJ. A solid phase immuno enzymological assay for the measurement of fibrinopeptide A. Thromb Res 1980; 20: 425-435.
• 31 Amiral J, Walenga JM, Fareed J. Development and performance characteristics of a competitive enzyme immunoassay for fibrinopeptide A. Semin Thromb Hemost 1984; 10: 228-242.
• 32 Stehle G, Harenberg J, Schmidt Gayk H, Zimmermann R. Fibrinopeptide A radioimmunoassay: a rapid and sensitive measurement of fibrin generation in vivo. J Clin Chem Clin Biochem 1983; 21: 91-95.
• 33 MacGregor I, McLaughlin L. Measurement of soluble fibrin in a variety of animal species. Thromb Res 1989; 55: 651-656.
• 34 Iversen LH, Thorlacius-Ussing O. Markers of fibrin formation in colorectal surgery: fibrinopeptide A and soluble fibrin. Thromb Res 1996; 81: 569-576.
• 35 Scheefers Borchel U, Muller Berghaus G, Fuhge P, Eberle R, Heimburger N. Discrimination between fibrin and fibrinogen by a monoclonal antibody against a synthetic peptide. Proc Natl Acad Sci USA 1985; 82: 7091-7095.
• 36 Nieuwenhuizen W, Hoegee-de Nobel E, Laterveer R. A rapid monoclonal antibody-based enzyme immunoassay (EIA) for the quantitative determination of soluble fibrin in plasma. Thromb Haemost 1992; 68: 273-277.
• 37 Blomback B, Yamashina I. On the N-terminal amino acids in fibrinogen and fibrin. Arkiv Kemi 1958; 12: 299-319.
• 38 Kierulf P, Abildgaard U. Studies on soluble fibrin in plasma I. N-terminal analysis of a modified fraction I (Cohn) from normal and thrombin-incubated plasma. Scand J Clin Lab Invest 1971; 28: 231-240.
• 39 Kierulf P. Studies on soluble fibrin in plasma. II. N-terminal analysis of a modified fraction I (Cohn) from patient plasmas. Scand J Clin Lab Invest 1973; 31: 37-42.
• 40 Chang ML, Wilson JE, Frenkel EP. Soluble fibrin complexes in experimental thrombotic states. J Lab Clin Med 1974; 84: 168-178.
• 41 Hafter R, Muller Berghaus G, von Hugo R, Graeff H. Estimation and characterization of soluble fibrin monomer complexes during endotoxin-induced intravascular coagulation. Thromb Res 1977; 10: 711-720.
• 42 Hafter R, von Hugo R, Baumgärtner M, Hiller FK, Graeff H. Temperature-dependent dissociation of soluble fibrin monomer complexes demonstrated by agarose gel filtration. Thromb Res 1980; 20: 325-333.
• 43 Derechin M. Caractères généraux de la paracoagulation fibrinolytique. Rev Hematol 1955; 10: 35-40.
• 44 Szuchet S, Derechin M. Relation between degree of fibrinogen proteolysis by plasmin and fibrinolytic paracoagulation. Proc Soc Exp Biol Med 1957; 94: 267-269.
• 45 Kopec M, Kowalski E, Stachurska J. Studies on paracoagulation: role of antithrombin VI. Thromb Diath Haemorrh 1961; 5: 285-295.
• 46 Kopec M, Wegrzynowicz Z, Latallo ZS. Precipitation of soluble fibrin monomer complexes (SFMC) by cellular basic proteins, and the antagonistic effect of sulfonated mucopolysaccharides. Proc Soc Exp Biol Med 1970; 135: 675-679.
• 47 Lipinski B, Worowski K. Detection of soluble fibrin monomer complexes in blood by means of protamine sulphate test. Thromb Diath Haemorrh 1968; 20: 44-49.
• 48 Seaman AJ. The recognition of intravascular clotting. Arch Intern Med 1970; 125: 1016-1021.
• 49 Gurewich V, Hutchison E. Detection of intravascular coagulation by a serial dilution protamine sulphate test. Ann Intern Med 1971; 75: 895-902.
• 50 Niewiarowski S, Gurewich V. Laboratory identification of intravascular coagulation. J Lab Clin Med 1971; 77: 665-676.
• 51 Sanfelippo MJ, Stevens DJ, Koenig RR. Protamine sulfate test for fibrin monomers. Am J Clin Pathol 1971; 56: 166-173.
• 52 Kidder WR, Logan LJ, Rapaport SI, Patch MJ. The plasma protamine paracoagulation test. Am J Clin Pathol 1972; 58: 675-686.
• 53 Thiele G, Fiedler H. Objektivierung des Protaminsulphattests durch photometrische Messungen. Zschr Inn Med 1976; 31: 542-544.
• 54 Wieding JU, Hosius C. Determination of soluble fibrin: a comparison of four different methods. Thromb Res 1992; 65: 745-756.
• 55 Wieding JU, Eisinger G, Kostering H. Determination of soluble fibrin by turbidimetry of its protamine sulphate-induced paracoagulation. J Clin Chem Clin Biochem 1989; 27: 57-63.
• 56 Wieding JU, Eisinger G, Köstering H. Determination of soluble fibrin by turbidimetry of the protamine sulphate paracoagulation. Excerpta Medica 1987; 745: 187-190.
• 57 Baughman DJ, Lytwyn A, Myrmel K. Detection of fibrin monomer and composition therefore. US Patent. 1980 US4210420
• 58 Godal HC, Abildgaard U. Gelation of soluble fibrin in plasma by ethanol. Scand J Haematol 1966; 3: 342-350.
• 59 Breen FA, Tullis JL. Ethanol gelation: a rapid screening test for intravascular coagulation. Ann Intern Med 1968; 69: 1197-1206.
• 60 Oehler G, Klaus H, Stotzer KE, Spanuth E. Detection of soluble fibrin monomer complexes. Comparison of a haemagglutination assay with the ethanol gelation test. Folia Haematol Leipz 1988; 115: 278-283.
• 61 Haselager EM, Vreeken J. Clinical significance of “circulating fibrin monomers.”. J Clin Pathol 1981; 34: 468-472.
• 62 Halvorsen S, Skjonsberg OH, Ruyter R, Godal HC. Comparison of methods for detecting soluble fibrin in plasma. An in vitro study. Thromb Res 1990; 57: 489-497.
• 63 Halvorsen S, Skjonsberg OH, Godal HC. Comparison of methods for detecting soluble fibrin in plasma from patients with venous thromboembolism. Thromb Res 1991; 61: 341-348.
• 64 Oehler G, Klaus H, Stotzer KE, Spanuth E. Detection of soluble fibrin monomer complexes. Comparison of a haemagglutination assay with the ethanol gelation test. Folia Haematol Int Mag Klin Morphol Blutforsch 1988; 115: 278-283.
• 65 Watanabe K, Tullis JL. Ristocetin precipitation test. A new simple method for detection of fibrin monomer and fibrin degradation products. Am J Clin Pathol 1978; 70: 691-696.
• 66 Pfliegler G, Vogel G, Boda Z, Zajka G, Rak K. Aggristin (ristomycin) precipitation test: a new tool for the detection of fibrin monomer and fibrin degradation products. Folia Haematol Int Mag Klin Morphol Blutforsch 1985; 112: 629-635.
• 67 Topfer G, Ehrhardt W, Dornheim G, Seifert A, Schmidt LH, Senger C, Funke U, Schulze M. Fibrin monomer complexes (SFMC) after substitution of antithrombin III (AT III) in consumption coagulopathy. Folia Haematol Int Mag Klin Morphol Blutforsch 1988; 115: 581-585.
• 68 Lutze G, Mittler U, Schulze M, Urbahn H. Detection of soluble fibrin monomer complexes by the netropsin precipitation test in childhood meningitis. Z Med Lab Diagn 1990; 31: 97-103.
• 69 Gonias SL, Pasqua JJ, Greenberg C, Pizzo SV. Precipitation of fibrinogen, fibrinogen degradation products and fibrin monomer by histone H3. Thromb Res 1985; 39: 97-116.
• 70 Heene DL, Matthias FR. Adsorption of fibrinogen derivatives on insolubilized fibrinogen and fibrinmonomer. Thromb Res 1973; 2: 137-154.
• 71 Matthias FR, Heene DL, Konradi E. Behavior of fibrinogen and fibrinogen degradation products towards insolubilized fibrinogen and fibrin monomer. Thromb Res 1973; 3: 657-664.
• 72 Matthias FR, Heene DL, Wegrzynowicz Z. Reduction of insolubilized fibrinogen. Thromb Res 1974; 4: 803-808.
• 73 Matthias FR, Reinicke R, Heene DL. Affinity chromatography and quantitation of soluble fibrin from plasma. Thromb Res 1977; 10: 365-384.
• 74 Thiel W, Delvos U, Muller Berghaus G. Quantitative assessment of soluble fibrin in plasma by affinity chromatography: a comparative study with desAA-fibrin, desAABB-fibrin and fibrinogen. Thromb Haemost 1985; 54: 533-538.
• 75 von Hugo R, Hafter R, Stemberger A, Graeff H. Complex formation of crosslinked fibrin oligomers with agarose-coupled fibrinogen and fibrin. Hoppe Seylers Z Physiol Chem 1977; 358: 1359-1363.
• 76 Semeraro N, Collen D. Affinity chromatography of soluble fibrin in human plasma on insolubilized fibrinogen and fragment D. Thromb Res 1978; 12: 1059-1070.
• 77 Bini A, Semeraro N, Collen D. Affinity chromatography of soluble fibrin in human plasma on insolubilized fibrinogen and on fragment D from fibrinogen, noncrosslinked or crosslinked fibrin. Thromb Res 1978; 13: 443-451.
• 78 Nilsen DW, Holm B, Brosstad F. Binding properties on Sepharose insolubilized fibrinogen and fibrin, of various species of fibrinogen and fibrin solubilized in plasma. Thromb Res 1986; 42: 449-459.
• 79 Becker U, Braun K, Heimburger N. Methods for the determination of soluble fibrin. European Patent. 1989 EP0306813
• 80 Kisker CT, Plummer G, Taylor B, Rush R. A method for measurement of fibrin monomer with the use of an immune precipitate of fibrinogen. J Lab Clin Med 1977; 89: 653-658.
• 81 Kisker CT. Detection of fibrin monomer: comparison of the immune precipitate method with the serial-dilution protamine sulfate test and the ethanol gelation test. Am J Clin Pathol 1979; 72: 405-409.
• 82 Largo R, Heller V, Straub PW. Detection of soluble intermediates of the fibrinogen–fibrin conversion using erythrocytes coated with fibrin monomers. Blood 1976; 47: 991-995.
• 83 Muller UP, Largo R, Straub PW. A sensitive latex agglutination method for the detection of soluble fibrin in plasma. Blutalkohol 1977; 35: 465-479.
• 84 Shainoff JR, Urbanic DA, DiBello PM, Valenzuela V. GPR-phoresis, a novel approach to determining fibrin monomer and other macromolecular derivatives of fibrinogen and fibrin in blood. Blood Coagul Fibrinolysis 1993; 4: 87-92.
• 85 Mosesson MW, Siebenlist KR, Voskuilen M, Nieuwenhuizen W. Evaluation of the factors contributing to fibrin-dependent plasminogen activation. Thromb Haemost 1998; 79: 796-801.
• 86 Suenson E, Bjerrum P, Holm A, Lind B, Meldal M, Selmer J, Petersen LC. The role of fragment X polymers in the fibrin enhancement of tissue plasminogen activator-catalyzed plasmin formation. J Biol Chem 1990; 265: 22228-22237.
• 87 Haddeland U, Bennick A, Brosstad F. Stimulating effect on tissue-type plasminogen activator—a new and sensitive indicator of denatured fibrinogen. Thromb Res 1995; 77: 329-336.
• 88 Haddeland U, Sletten K, Bennick A, Brosstad F. Freeze-dried fibrinogen or fibrinogen in EDTA stimulate the tissue-type plasminogen activator-catalysed conversion of plasminogen to plasmin. Blood Coagul Fibrinolysis 1994; 5: 575-581.
• 89 Gron B, Bennick A, Filion Myklebust C, Matsueda GR, Nieuwenhuizen W, Brosstad F. Soluble, cross-linked fibrin(ogen) hybrid oligomers do not stimulate t-PA conversion of plasminogen. Thromb Res 1992; 66: 231-238.
• 90 van Wersch JW. Adaptation and evaluation of a chromogenic test procedure for fibrin monomers on a centrifugal analyzer. J Clin Chem Clin Biochem 1990; 28: 169-174.
• 91 Plow EF, Edgington TS. Immunobiology of fibrinogen: emergence of neoantigenic expressions during physiologic cleavage in vitro and in vivo. J Clin Invest 1973; 52: 273-281.
• 92 Pacella BLJ, Hui KY, Haber E, Matsueda GR. Induction of fibrinspecific antibodies by immunization with synthetic peptides that correspond to amino termini of thrombin cleavage sites. Mol Immunol 1983; 20: 521-527.
• 93 Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe ME. Specificity of a monoclonal antibody for the NH2-terminal region of fibrin. Mol Immunol 1984; 21: 89-94.
• 94 Hui KY, Haber E, Matsueda GR. Monoclonal antibodies of predetermined specificity for fibrin: a rational approach to monoclonal antibody production. Hybridoma 1986; 5: 215-222.
• 95 Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen. Science 1983; 222: 1129-1132.
• 96 Higgins DL, Lewis SD, Shafer JA. Steady state kinetic parameters for the thrombin-catalyzed conversion of human fibrinogen to fibrin. J Biol Chem 1983; 258: 9276-9282.
• 97 Hurlet Jensen A, Cummins HZ, Nossel HL, Liu CY. Fibrin polymerization and release of fibrinopeptide B by thrombin. Thromb Res 1982; 27: 419-427.
• 98 Muller Berghaus G, Scheefers Borchel U, Fuhge P, Eberle R, Heimburger N. Detection of fibrin in plasma by a monoclonal antibody against the amino-terminus of the α-chain of fibrin. Scand J Clin Lab Invest 1985; 45 (Suppl) 145-151.
• 99 Mao SJ, Rechtin AE, Krstenansky JL, Jackson RL. Characterization of a monoclonal antibody specific to the amino terminus of the α-chain of human fibrin. Thromb Haemost 1990; 63: 445-448.
• 100 Lill H, Spannagl M, Trauner A, Schramm W, Schuller D, Ofenloch Haehnle B, Draeger B, Naser W, Dessauer A. A new immunoassay for soluble fibrin enables a more sensitive detection of the activation state of blood coagulation in vivo. Blood Coagul Fibrinolysis 1993; 4: 97-102.
• 101 Dempfle CE, Dollman M, Lill H, Puzzovio D, Dessauer A, Heene DL. Binding of a new monoclonal antibody against N-terminal heptapeptide of fibrin α-chain to fibrin polymerization site “A:” effects of fibrinogen and fibrinogen derivatives, and pretreatment of samples with NaSCN. Blood Coagul Fibrinolysis 1993; 4: 79-86.
• 102 Cierniewski CS, Kloczewiak M, Budzynski AZ. Expression of primary polymerization sites in the D domain of human fibrinogen depends on intact conformation. J Biol Chem 1986; 261: 9116-9121.
• 103 Verheijen JH, Nieuwenhuizen W, Wijngaards G. Activation of plasminogen by tissue activator is increased specifically in the presence of certain soluble fibrin(ogen) fragments. Thromb Res 1982; 27: 377-385.
• 104 Nieuwenhuizen W, Verheijen JH, Vermond A, Chang GT. Plasminogen activation by tissue activator is accelerated in the presence of fibrin(ogen) cyanogen bromide fragment FCB-2. Biochim Biophys Acta 1983; 755: 531-533.
• 105 Nieuwenhuizen W, Vermond A, Voskuilen M, Traas DW. Identification of a site in fibrin(ogen) which is involved in the acceleration of plasminogen activation by tissue-type plasminogen activator. Biochim Biophys Acta 1983; 748: 86-92.
• 106 Schielen WJ, Voskuilen M, Adams PJ, Tesser GI, Nieuwenhuizen W. Structural requirements of fibrinogen A α-(148-160) for the enhancement of the rate of plasminogen activation by t-PA. Blood Coagul Fibrinolysis 1990; 1: 521-524.
• 107 Schielen WJ, Adams HP, Voskuilen M, Tesser GI, Nieuwenhuizen W. The sequence A α-(154-159) of fibrinogen is capable of accelerating the t-PA catalysed activation of plasminogen. Blood Coagul Fibrinolysis 1991; 2: 465-470.
• 108 Schielen JG, Adams HP, Voskuilen M, Tesser GJ, Nieuwenhuizen W. Structural requirements of position A α-157 in fibrinogen for the fibrin-induced rate enhancement of the activation of plasminogen by tissue-type plasminogen activator. Biochem J 1991; 276: 655-659.
• 109 Schielen WJ, Voskuilen M, Tesser GI, Nieuwenhuizen W. The sequence A α-(148-160) in fibrin, but not in fibrinogen, is accessible to monoclonal antibodies. Proc Natl Acad Sci USA 1989; 86: 8951-8954.
• 110 Nieuwenhuizen W. Sites in fibrin involved in the acceleration of plasminogen activation by t-PA. Possible role of fibrin polymerisation. Thromb Res 1994; 75: 343-347.
• 111 Schielen WJ, Adams HP, Van Leuven K, Voskuilen M, Tesser GI, Nieuwenhuizen W. The sequence γ-(312-324) is a fibrin-specific epitope. Blood 1991; 77: 2169-2173.
• 112 Ginsberg JS, Siragusa S, Douketis J, Johnston M, Moffat K, Stevens P, Brill Edwards P, Panju A, Patel A. Evaluation of a soluble fibrin assay in patients with suspected deep vein thrombosis. Thromb Haemost 1995; 74: 833-836.
• 113 Holm B, Godal HC. Quantitation of the three normally-occurring plasma fibrinogens in health and during so-called “acute phase” by SDS electrophoresis of fibrin obtained from EDTA-plasma. Thromb Res 1984; 35: 279-290.
• 114 Holm B, Nilsen DW, Kierulf P, Godal HC. Purification and characterization of 3 fibrinogens with different molecular weights obtained from normal human plasma. Thromb Res 1985; 37: 165-176.
• 115 Nakashima A, Sasaki S, Miyazaki K, Miyata T, Iwanaga S. Human fibrinogen heterogeneity: the COOH-terminal residues of defective A α chains of fibrinogen II. Blood Coagul Fibrinolysis 1992; 3: 361-370.
• 116 Dempfle CE, Pfitzner SA, Schott D, Niessen KH, Heene DL. Fibrinogen heterogeneity in homozygous plasminogen deficiency type I: further evidence that plasmin is not involved in formation of LMW-$$$$ and LMW’-fibrinogen. Thromb Haemost 1997; 77: 879-883.
• 117 Dempfle CE, Pfitzner SA, Dollman M, Huck K, Stehle G, Heene DL. Comparison of immunological and functional assays for measurement of soluble fibrin. Thromb Haemost 1995; 74: 673-679.
• 118 Bach Gansmo ET, Halvorsen S, Godal HC, Skjonsberg OH. Degradation of the α-chain of fibrin by human neutrophil elastase reduces the stimulating effect of fibrin on plasminogen activation. Thromb Res 1994; 75: 307-317.
• 119 Graeff H, Ernst E, Bocaz JA, von Hugo R, Hafter R. Evaluation of hypercoagulability in septic abortion. Haemostasis 1976; 5: 285-294.
• 120 Soe G, Kohno I, Inuzuka K, Itoh Y, Matsuda M. A monoclonal antibody that recognizes a neo-antigen exposed in the E domain of fibrin monomer complexes with fibrinogen or its derivatives: its application to the measurement of soluble fibrin in plasma. Blood 1996; 88: 2109-2117.
• 121 Carville DG, Dimitrijevic N, Walsh M, Digirolamo T, Brill EM, Drew N, Gargan PE. Thrombus precursor protein (TpP): marker of thrombosis early in the pathogenesis of myocardial infarction. Clin Chem 1996; 42: 1537-1541.
• 122 Gargan PE, Carville DG, Dimitrijevic N. Method of producing fibrin-specific antibodies using soluble fibrin polymers as an immunogen. US Patent. 1998 US5837540
• 123 Halvorsen S, Skjonsberg OH, Godal HC. Thrombin treated plasma employed as a standard for determination of soluble fibrin. Thromb Res 1993; 72: 305-313.
• 124 Lijnen HR, Van Hoef B, de Cock F, Collen D. Effect of fibrin-like stimulators on the activation of plasminogen by tissue-type plasminogen activator (t-PA)-studies with active site mutagenized plasminogen and plasmin resistant t-PA. Thromb Haemost 1990; 64: 61-68.
• 125 Procyk R, Medved L, Engelke KJ, Kudryk B, Blomback B. Nonclottable fibrin obtained from partially reduced fibrinogen: characterization and tissue plasminogen activator stimulation. Biochemistry 1992; 31: 2273-2278.
• 126 Adema E, Gebert U. Pooled patient samples as reference material for D-Dimer. Thromb Res 1995; 80: 85-88.
• 127 Rotker J, Preissner KT, Muller Berghaus G. Soluble fibrin consists of fibrin oligomers of heterogeneous distribution. Eur J Biochem 1986; 155: 583-588.
• 128 Rahr HB, Danielsen D, Andersen BS, Borris LC, Lassen MR. Poor correlation between soluble fibrin concentrations measured by two commercially available immunoassays. Thromb Res 1996; 81: 607-614.
• 129 Lipinski B, Worowski K, Jeljaszewicz J, Niewiarowski S, Rejniak L. Participation of soluble fibrin monomer complexes and platelet factor 4 in the generalized Shwartzman reaction. Thromb Diath Haemorrh 1968; 20: 285-295.
• 130 Phillips LL. Fibrin monomer as a test for intravascular coagulation. Obstet Gynecol 1975; 45: 124-128.
• 131 Nakagawa K, Tsuji H, Masuda H, Yamada K, Yamada Y, Yoneda M, Takada O, Tamagaki T, Yamagami M, Uno M. et al. Plasma levels of soluble fibrin in patients with malignancy-associated disseminated intravascular coagulation. Blood Coagul Fibrinolysis 1994; 5: 725-730.
• 132 Bredbacka S, Blomback M, Wiman B, Pelzer H. Laboratory methods for detecting disseminated intravascular coagulation (DIC): new aspects. Acta Anaesthesiol Scand 1993; 37: 125-130.
• 133 Bredbacka S, Blomback M, Wiman B, Pelzer H. Disseminated intravascular coagulation in neurosurgical patients: Diagnosis by laboratory methods. J Neurosurg Anesthesiol 1992; 4: 128-133.
• 134 Bredbacka S, Blomback M, Wiman B. Soluble fibrin: a predictor for the development and outcome of multiple organ failure. Am J Hematol 1994; 46: 289-294.
• 135 Graeff H, von Hugo R, Schrock R. Recent aspects of hemostasis, hematology and hemorheology in preeclampsia-eclampsia. Eur J Obstet Gynecol Reprod Biol 1984; 17: 91-102.
• 136 Ostlund E, Bremme K, Wiman B. Soluble fibrin in plasma as a sign of activated coagulation in patients with preganancy complications. Acta Obstet Gynecol Scand 1998; 77: 165-169.
• 137 Freyburger G, Trillaud H, Labrouche S, Gauthier P, Javorschi S, Bernard P, Grenier N. D-dimer strategy in thrombosis exclusion. A gold standard study in 100 patients suspected of venous thrombosis or pulmonary embolism: 8 DD methods compared. Thromb Haemost 1998; 79: 32-37.
• 138 Legnani C, Pancani C, Palareti G, Guazzaloca G, Fortunato G, Grauso F, Golfieri R, Gianpalma E, Coccheri S. Comparison of new rapid methods for D-dimer measurement to exclude deep vein thrombosis in symptomatic out-PAtients. Blood Coagul Fibrinolysis 1997; 8: 296-302.
• 139 Ginsberg JS, Siragusa S, Douketis J, Johnston M, Moffat K, Donovan D, McGinnis J, Brill-Edwards P, Panju A, Patel A, Weitz JI. Evaluation of a soluble fibrin assay in patients with suspected pulmonary embolism. Thromb Haemost 1996; 75: 551-554.
• 140 Hansson PO, Eriksson H, Eriksson E, Jagenburg R, Lukes P, Risberg B. Can laboratory testing improve screening strategies for deep vein thrombosis at an emergency unit? [see comments]. J Intern Med 1994; 235: 143-151.
• 141 Vogel G, Dempfle CE, Spannagl M, Leskopf W. The value of quantitative fibrin monomer determination in the early diagnosis of postoperative deep vein thrombosis. Thromb Res 1996; 81: 241-251.
• 142 Rahr HB, Sorensen JV, Larsen JF, Jensen FS, Bredahl C, Nieuwenhuizen W. Haemostatic activation before and after surgery in patients with and without gastric malignancy. Thromb Haemost 1994; 71: 713-718.
• 143 Iversen LH, Thorlacius Ussing O, Okholm M. Soluble fibrin in plasma before and after surgery for benign and malignant colorectal disease. Thromb Res 1995; 79: 471-481.
• 144 Ames PR, Pyke S, Iannaccone L, Brancaccio V. Antiphospholipid antibodies, haemostatic variables and thrombosis—a survey of 144 patients. Thromb Haemost 1995; 73: 768-773.
• 145 Ruffatti A, Aversa S, Del Ross T, Tonetto S, Fiorentino M, Todesco S. Antiphospholipid antibody syndrome associated with ovarian cancer. A new paraneoplastic syndrome?. J Rheumatol 1994; 21: 2162-2163.
• 146 Young JA, Kisker CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg 1978; 26: 231-240.
• 147 Slaughter TF, LeBleu TH, Douglas JMJ, Leslie JB, Parker JK, Greenberg CS. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 1994; 80: 520-526.